Company intelligence / Profile preview

NeuroDerm Ltd.

Ownership: Private
Development stage: Phase 3

Overview

Lead product candidate ND0612 had commenced Phase III clinical trials in the U.S. and Europe as of 2017, with expected launch in FY2019. ND0612 is designed for advanced stage Parkinson's disease patients for whom oral levodopa is no longer effective in controlling motor complications[1][3].

Therapeutic areas: Neurology
Modalities: Drug-device combinationsliquid levodopa and carbidopa formulations
Industry: Biotech

Drug pipeline

4 assets

ND0612

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on NeuroDerm Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroDerm Ltd..

Explore the full profile